Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Sclerosis | 50 | 2022 | 3002 | 6.310 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 17 | 2022 | 509 | 3.510 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 6 | 2021 | 222 | 2.950 |
Why?
|
Magnetic Resonance Imaging | 71 | 2022 | 34430 | 2.140 |
Why?
|
Cerebral Cortex | 15 | 2019 | 5694 | 1.890 |
Why?
|
Spinal Cord | 7 | 2020 | 1808 | 0.960 |
Why?
|
Image Interpretation, Computer-Assisted | 6 | 2020 | 3413 | 0.950 |
Why?
|
Brain | 33 | 2021 | 25206 | 0.940 |
Why?
|
Brain Mapping | 18 | 2019 | 6539 | 0.810 |
Why?
|
Migraine with Aura | 3 | 2020 | 199 | 0.720 |
Why?
|
Trigeminal Nerve | 2 | 2014 | 259 | 0.720 |
Why?
|
Nerve Degeneration | 2 | 2017 | 781 | 0.710 |
Why?
|
Hemostatics | 1 | 2021 | 229 | 0.700 |
Why?
|
Interferon-beta | 5 | 2015 | 325 | 0.670 |
Why?
|
Thalamus | 4 | 2020 | 1012 | 0.650 |
Why?
|
Nerve Fibers, Myelinated | 2 | 2015 | 980 | 0.630 |
Why?
|
Receptors, GABA | 3 | 2018 | 264 | 0.610 |
Why?
|
Pyrimidines | 3 | 2019 | 2930 | 0.580 |
Why?
|
Periaqueductal Gray | 2 | 2016 | 120 | 0.540 |
Why?
|
Diffusion Magnetic Resonance Imaging | 7 | 2019 | 2690 | 0.520 |
Why?
|
Somatosensory Cortex | 4 | 2013 | 533 | 0.510 |
Why?
|
Meningitis | 1 | 2015 | 226 | 0.480 |
Why?
|
Positron-Emission Tomography | 9 | 2020 | 6270 | 0.460 |
Why?
|
Paraparesis, Tropical Spastic | 1 | 2012 | 29 | 0.450 |
Why?
|
Neural Pathways | 4 | 2016 | 3020 | 0.450 |
Why?
|
Migraine without Aura | 1 | 2013 | 87 | 0.450 |
Why?
|
Leukoencephalopathies | 3 | 2022 | 251 | 0.440 |
Why?
|
Cortical Spreading Depression | 2 | 2020 | 278 | 0.430 |
Why?
|
Cerebellum | 1 | 2019 | 1479 | 0.430 |
Why?
|
Inflammation | 4 | 2020 | 10081 | 0.430 |
Why?
|
Gadolinium | 4 | 2015 | 910 | 0.410 |
Why?
|
Migraine Disorders | 2 | 2014 | 1575 | 0.400 |
Why?
|
Microglia | 1 | 2019 | 1168 | 0.400 |
Why?
|
Disease Progression | 15 | 2020 | 13215 | 0.380 |
Why?
|
Atrophy | 9 | 2022 | 1499 | 0.370 |
Why?
|
Myelin Sheath | 3 | 2020 | 648 | 0.370 |
Why?
|
Adult | 57 | 2020 | 212266 | 0.370 |
Why?
|
Demyelinating Diseases | 2 | 2022 | 367 | 0.330 |
Why?
|
Motor Cortex | 5 | 2009 | 961 | 0.330 |
Why?
|
Executive Function | 1 | 2016 | 1304 | 0.320 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1142 | 0.320 |
Why?
|
Hyperesthesia | 1 | 2007 | 17 | 0.320 |
Why?
|
Humans | 85 | 2022 | 715777 | 0.310 |
Why?
|
Disability Evaluation | 8 | 2019 | 1821 | 0.300 |
Why?
|
Axons | 6 | 2019 | 1732 | 0.300 |
Why?
|
Oxygen | 4 | 2015 | 4162 | 0.290 |
Why?
|
Male | 57 | 2020 | 350324 | 0.280 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 2007 | 250 | 0.280 |
Why?
|
Amygdala | 1 | 2013 | 1260 | 0.280 |
Why?
|
Memory | 2 | 2006 | 2143 | 0.270 |
Why?
|
Female | 57 | 2020 | 377204 | 0.260 |
Why?
|
Cerebral Veins | 2 | 2016 | 155 | 0.260 |
Why?
|
Attention | 2 | 2006 | 2386 | 0.250 |
Why?
|
4-Aminopyridine | 1 | 2004 | 85 | 0.250 |
Why?
|
Energy Metabolism | 2 | 2014 | 2968 | 0.250 |
Why?
|
Potassium Channel Blockers | 1 | 2004 | 172 | 0.250 |
Why?
|
Cognition Disorders | 3 | 2015 | 3975 | 0.240 |
Why?
|
Synaptic Transmission | 2 | 2014 | 1191 | 0.240 |
Why?
|
Image Processing, Computer-Assisted | 12 | 2020 | 9004 | 0.240 |
Why?
|
Middle Aged | 35 | 2020 | 214639 | 0.230 |
Why?
|
Brain Stem | 1 | 2007 | 838 | 0.210 |
Why?
|
Neuronal Plasticity | 4 | 2006 | 1406 | 0.210 |
Why?
|
Prospective Studies | 9 | 2022 | 51315 | 0.200 |
Why?
|
Reproducibility of Results | 8 | 2022 | 19537 | 0.200 |
Why?
|
Immunotherapy | 1 | 2015 | 4095 | 0.190 |
Why?
|
Neuropsychological Tests | 6 | 2018 | 6873 | 0.180 |
Why?
|
Meninges | 1 | 2020 | 184 | 0.170 |
Why?
|
Motor Activity | 4 | 2005 | 2774 | 0.170 |
Why?
|
Motor Neuron Disease | 1 | 2017 | 109 | 0.160 |
Why?
|
Nerve Regeneration | 2 | 2019 | 801 | 0.150 |
Why?
|
Myotonic Dystrophy | 2 | 2009 | 77 | 0.150 |
Why?
|
Gadolinium DTPA | 2 | 2004 | 830 | 0.150 |
Why?
|
Fatigue | 2 | 2004 | 1453 | 0.150 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 1 | 2022 | 828 | 0.150 |
Why?
|
Evoked Potentials, Motor | 3 | 2009 | 431 | 0.140 |
Why?
|
Encephalitis | 1 | 2019 | 440 | 0.140 |
Why?
|
Case-Control Studies | 5 | 2018 | 21797 | 0.130 |
Why?
|
Algorithms | 2 | 2014 | 13758 | 0.130 |
Why?
|
Electromagnetic Phenomena | 1 | 2015 | 153 | 0.130 |
Why?
|
Anisotropy | 1 | 2017 | 1245 | 0.130 |
Why?
|
Sensitivity and Specificity | 4 | 2018 | 14902 | 0.130 |
Why?
|
Afferent Pathways | 1 | 2014 | 316 | 0.120 |
Why?
|
Blood-Brain Barrier | 1 | 1999 | 1004 | 0.120 |
Why?
|
Functional Laterality | 4 | 2015 | 2288 | 0.110 |
Why?
|
Neuroglia | 1 | 2017 | 919 | 0.110 |
Why?
|
Adjuvants, Immunologic | 3 | 2002 | 975 | 0.110 |
Why?
|
Fibromyalgia | 1 | 2016 | 362 | 0.110 |
Why?
|
Movement Disorders | 1 | 2015 | 427 | 0.100 |
Why?
|
Corpus Callosum | 3 | 2022 | 728 | 0.100 |
Why?
|
Imaging, Three-Dimensional | 3 | 2015 | 4029 | 0.100 |
Why?
|
Nociceptors | 1 | 2014 | 441 | 0.100 |
Why?
|
Sleep Apnea Syndromes | 1 | 2017 | 869 | 0.090 |
Why?
|
Physical Stimulation | 2 | 2007 | 540 | 0.080 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2018 | 1351 | 0.080 |
Why?
|
Carotid Stenosis | 1 | 2015 | 812 | 0.080 |
Why?
|
Touch | 2 | 2007 | 311 | 0.080 |
Why?
|
Consensus | 1 | 2016 | 2743 | 0.080 |
Why?
|
Severity of Illness Index | 6 | 2018 | 15909 | 0.070 |
Why?
|
Trigeminal Nuclei | 1 | 2006 | 44 | 0.070 |
Why?
|
Cohort Studies | 4 | 2018 | 40029 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2019 | 13643 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2018 | 23438 | 0.070 |
Why?
|
Intracranial Arteriovenous Malformations | 1 | 2009 | 385 | 0.070 |
Why?
|
Nerve Net | 1 | 2018 | 2139 | 0.070 |
Why?
|
Follow-Up Studies | 8 | 2019 | 39300 | 0.060 |
Why?
|
Societies, Medical | 1 | 2016 | 3754 | 0.060 |
Why?
|
Neurons, Afferent | 1 | 2007 | 512 | 0.060 |
Why?
|
Psychomotor Performance | 3 | 2007 | 1937 | 0.060 |
Why?
|
Image Enhancement | 1 | 2014 | 2979 | 0.060 |
Why?
|
Age Distribution | 1 | 2009 | 2942 | 0.060 |
Why?
|
Cognition | 2 | 2014 | 6077 | 0.060 |
Why?
|
Pain Threshold | 1 | 2007 | 592 | 0.060 |
Why?
|
Risk | 1 | 2015 | 9801 | 0.060 |
Why?
|
Young Adult | 6 | 2021 | 56226 | 0.060 |
Why?
|
Movement | 1 | 2009 | 1473 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18784 | 0.050 |
Why?
|
Reaction Time | 2 | 2007 | 2111 | 0.050 |
Why?
|
Magnetics | 1 | 2004 | 643 | 0.050 |
Why?
|
Models, Neurological | 3 | 2009 | 1781 | 0.050 |
Why?
|
Disabled Persons | 3 | 2005 | 1149 | 0.050 |
Why?
|
Pyramidal Tracts | 1 | 2002 | 259 | 0.050 |
Why?
|
Aged | 8 | 2020 | 162448 | 0.050 |
Why?
|
Brain Chemistry | 2 | 2013 | 1015 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2009 | 15199 | 0.050 |
Why?
|
Fibrin | 1 | 2022 | 515 | 0.040 |
Why?
|
Hemostasis | 1 | 2022 | 450 | 0.040 |
Why?
|
Creatine | 1 | 2001 | 413 | 0.040 |
Why?
|
Electromyography | 1 | 2004 | 1372 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7446 | 0.040 |
Why?
|
Antibodies, Antinuclear | 1 | 2000 | 340 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2004 | 2015 | 0.040 |
Why?
|
Aspartic Acid | 1 | 2001 | 579 | 0.040 |
Why?
|
Occipital Lobe | 1 | 2020 | 381 | 0.040 |
Why?
|
Home Care Services | 1 | 2004 | 593 | 0.040 |
Why?
|
Diffusion Tensor Imaging | 2 | 2019 | 2193 | 0.040 |
Why?
|
Mental Recall | 1 | 2004 | 1192 | 0.040 |
Why?
|
Memory, Short-Term | 1 | 2004 | 932 | 0.040 |
Why?
|
Estradiol | 1 | 2005 | 1978 | 0.040 |
Why?
|
Spinal Cord Diseases | 1 | 2019 | 293 | 0.040 |
Why?
|
Carbon Radioisotopes | 1 | 2017 | 612 | 0.040 |
Why?
|
Menstrual Cycle | 1 | 1999 | 533 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2015 | 62004 | 0.040 |
Why?
|
Apomorphine | 1 | 1995 | 150 | 0.040 |
Why?
|
Observer Variation | 2 | 2018 | 2676 | 0.030 |
Why?
|
Prognosis | 3 | 2018 | 29005 | 0.030 |
Why?
|
Contrast Media | 4 | 2004 | 5276 | 0.030 |
Why?
|
Skull | 1 | 2020 | 814 | 0.030 |
Why?
|
Stroke | 1 | 2017 | 9505 | 0.030 |
Why?
|
Central Nervous System | 1 | 2022 | 1291 | 0.030 |
Why?
|
Testosterone | 1 | 2005 | 2359 | 0.030 |
Why?
|
Down-Regulation | 1 | 2002 | 3066 | 0.030 |
Why?
|
Antibodies | 1 | 2002 | 2432 | 0.030 |
Why?
|
Electrocardiography | 1 | 2007 | 6386 | 0.030 |
Why?
|
Narcotics | 1 | 1995 | 325 | 0.030 |
Why?
|
Caregivers | 1 | 2004 | 1925 | 0.030 |
Why?
|
Dopamine Agonists | 1 | 1995 | 352 | 0.030 |
Why?
|
Heart | 1 | 2006 | 4315 | 0.030 |
Why?
|
Organ Size | 1 | 2018 | 2278 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2002 | 1842 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2002 | 1571 | 0.030 |
Why?
|
Estrogens | 1 | 1999 | 1529 | 0.030 |
Why?
|
Pattern Recognition, Automated | 1 | 2018 | 1019 | 0.030 |
Why?
|
Adolescent | 8 | 2020 | 85155 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2002 | 1785 | 0.030 |
Why?
|
Paresis | 2 | 2002 | 175 | 0.030 |
Why?
|
Artificial Intelligence | 1 | 2022 | 1744 | 0.030 |
Why?
|
Health Status | 1 | 2004 | 4001 | 0.020 |
Why?
|
Polysomnography | 1 | 2017 | 1710 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2004 | 11945 | 0.020 |
Why?
|
Cocaine | 1 | 1995 | 994 | 0.020 |
Why?
|
Neurophysiology | 1 | 2009 | 102 | 0.020 |
Why?
|
Transcranial Magnetic Stimulation | 2 | 2009 | 1311 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2018 | 6501 | 0.020 |
Why?
|
Paresthesia | 1 | 2009 | 161 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 3687 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2015 | 72443 | 0.020 |
Why?
|
Recurrence | 1 | 1999 | 8240 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6722 | 0.020 |
Why?
|
Regression Analysis | 2 | 2007 | 6495 | 0.020 |
Why?
|
Reference Values | 2 | 2004 | 5050 | 0.020 |
Why?
|
Depression | 1 | 2004 | 7268 | 0.020 |
Why?
|
Pons | 1 | 2006 | 251 | 0.020 |
Why?
|
Mathematical Computing | 1 | 2004 | 148 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 13217 | 0.020 |
Why?
|
Pilot Projects | 1 | 2017 | 8075 | 0.020 |
Why?
|
Trinucleotide Repeats | 1 | 2004 | 269 | 0.020 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2004 | 375 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2022 | 22665 | 0.010 |
Why?
|
Cerebral Angiography | 1 | 2009 | 1375 | 0.010 |
Why?
|
Motor Skills | 1 | 2006 | 524 | 0.010 |
Why?
|
Electric Stimulation | 1 | 2007 | 1759 | 0.010 |
Why?
|
Genes, Dominant | 1 | 2004 | 904 | 0.010 |
Why?
|
Dominance, Cerebral | 1 | 2002 | 656 | 0.010 |
Why?
|
Neurologic Examination | 1 | 2004 | 954 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12480 | 0.010 |
Why?
|
Optic Neuritis | 1 | 2002 | 168 | 0.010 |
Why?
|
Patient Dropouts | 1 | 2002 | 425 | 0.010 |
Why?
|
Drug Tolerance | 1 | 2002 | 385 | 0.010 |
Why?
|
Hemodynamics | 1 | 2009 | 4214 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 2004 | 1808 | 0.010 |
Why?
|
Parietal Lobe | 1 | 2002 | 814 | 0.010 |
Why?
|
Hand | 1 | 2002 | 853 | 0.010 |
Why?
|
Drug Interactions | 1 | 2002 | 1468 | 0.010 |
Why?
|
Steroids | 1 | 2002 | 888 | 0.010 |
Why?
|
Affect | 1 | 2004 | 1494 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2002 | 1334 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2002 | 1511 | 0.010 |
Why?
|
Mice | 1 | 2022 | 80375 | 0.010 |
Why?
|
Deoxyglucose | 1 | 1995 | 341 | 0.010 |
Why?
|
Time Factors | 3 | 2002 | 40875 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2002 | 5031 | 0.010 |
Why?
|
Patient Care Team | 1 | 2004 | 2581 | 0.010 |
Why?
|
Animals | 2 | 2022 | 169420 | 0.010 |
Why?
|
Acute Disease | 1 | 2002 | 7140 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2002 | 6552 | 0.010 |
Why?
|
Sex Factors | 1 | 2005 | 10666 | 0.010 |
Why?
|
Software | 1 | 2004 | 4396 | 0.010 |
Why?
|
Neurons | 1 | 2009 | 9375 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2015 | 58323 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 1995 | 8545 | 0.000 |
Why?
|
Blood Glucose | 1 | 1995 | 6259 | 0.000 |
Why?
|
Rats | 1 | 1995 | 24860 | 0.000 |
Why?
|
Concepts
(222)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(34)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_